

## Special Issue

# Genetic and Epigenetic Mechanisms in Brain and Spinal Tumors

### Message from the Guest Editors

This Special Issue, titled "Genetic and Epigenetic Mechanisms in Brain and Spinal Tumors", will mainly focus on understanding the role of genetic and epigenetic alterations as a driving force of oncogenesis and therapeutic resistance in brain and spinal neoplasms. By investigating the genetic and epigenetic mechanisms involved in brain and spinal tumors, this Special Issue aims to gain insights into the underlying biology of brain and spinal tumors, discover new diagnostic and prognostic markers, develop more effective treatments, and ultimately improve patient outcomes. Potential topics include, but are not limited to:

- Recent advances in genomics and epigenomics biomarkers;
- Novel therapeutic drugs based on genetic and epigenetic subtypes;
- Novel tools for patient diagnosis and prognostication;
- Cell signaling pathways based on genetic and epigenetic alterations.

---

### Guest Editors

Dr. Prit Benny Malgulwar

Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Dr. Yogesh Srivastava

Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX, USA

---

### Deadline for manuscript submissions

closed (30 September 2023)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/174305](https://mdpi.com/si/174305)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).